Cfo
CurrentPalvella Therapeutics is a late clinical-stage biopharmaceutical company whose vision is to become the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Our versatile QTORIN platform is designed to generate new therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of rare skin diseases. Our lead product candidate, QTORIN rapamycin, is in clinical development for three genetic skin diseases: pachyonychia congenita, microcystic lymphatic malformations, and basal cell carcinomas in Gorlin syndrome patients. We have three ongoing clinical trials, including VAPAUS, our randomized, double-blind, Phase 3 clinical trial for the treatment of pachyonychia congenita.